Life‐threatening pneumonitis after first‐line treatment with osimertinib for primary T790M mutated non‐small cell lung cancer

Epithelial growth factor receptor (EGFR) directed tyrosine kinase inhibitor (TKI) treatment is the standard approach in patients with advanced, EGFR‐mutated non‐small cell lung cancer (NSCLC). Although benefit/risk ratio is favorable for these TKI and side effects are manageable in the vast majority...

Descripción completa

Detalles Bibliográficos
Autores principales: Häntschel, Maik, Niebling, Johannes, Häring, Almut, Häring, Max‐Felix, Groß, Thorben, Horger, Marius, Riessen, Reimer, Haap, Michael, Lewis, Richard A, Böckeler, Michael, Hetzel, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327687/
https://www.ncbi.nlm.nih.gov/pubmed/32374485
http://dx.doi.org/10.1111/1759-7714.13476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327687/
https://www.ncbi.nlm.nih.gov/pubmed/32374485
http://dx.doi.org/10.1111/1759-7714.13476

Ejemplares similares